Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Adaptimmune Therapeutics plc
  6. Summary
    ADAP   US00653A1079

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
Delayed Quote. Delayed Nasdaq - 06/18 04:00:01 pm
3.95 USD   -5.50%
06/18European ADRs Down More Than 2% Friday as Banks, Drillers Drop
MT
06/16European ADRs Flat in Wednesday Morning Trading
MT
06/15European ADRs Flat in Tuesday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
4.49(c) 4.14(c) 4.03(c) 4.18(c) 3.95(c) Last
679 543 2 664 664 1 274 237 1 385 990 2 241 347 Volume
+0.67% -7.80% -2.66% +3.72% -5.50% Change
More quotes
Financials (USD)
Sales 2021 1,80 M - -
Net income 2021 -159 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,96x
Yield 2021 -
Sales 2022 9,60 M - -
Net income 2022 -182 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,67x
Yield 2022 -
Capitalization 614 M 614 M -
Capi. / Sales 2021 341x
Capi. / Sales 2022 64,0x
Nbr of Employees 462
Free-Float 7,23%
More Financials
Company
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for... 
Read more
More about the company
Ratings of Adaptimmune Therapeutics plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ADAPTIMMUNE THERAPEUTICS PLC
06/18European ADRs Down More Than 2% Friday as Banks, Drillers Drop
MT
06/16European ADRs Flat in Wednesday Morning Trading
MT
06/15European ADRs Flat in Tuesday Trading
MT
06/08European ADRs Nudge Higher in Tuesday Trading
MT
06/07European ADRs Nudge Lower in Monday Trading
MT
06/01European ADRs Rise 0.5% Tuesday; Rio Tinto, Equinor Among Leaders
MT
06/01ADAPTIMMUNE THERAPEUTICS  : June 2021 Corporate Deck
PU
05/28European ADRs Move Higher in Friday Trading
MT
05/28ADAPTIMMUNE THERAPEUTICS  : Barclays Starts Adaptimmune Therapeutics at Underwei..
MT
05/26European ADRs Trading Nearly Flat Wednesday; IDEX a Standout
MT
05/20ADAPTIMMUNE THERAPEUTICS  : To Preset Initial Phase 2 Data on Afamitresgene Auto..
MT
05/20European ADRs Move Higher in Thursday Trading
MT
05/19ADAPTIMMUNE THERAPEUTICS  : Company Presentation of Data at ASCO 2021 Annual Mee..
PU
05/19ADAPTIMMUNE THERAPEUTICS  : Two Complete Responses and Response Rate of 41% for ..
PU
05/19ADAPTIMMUNE THERAPEUTICS PLC  : Regulation FD Disclosure, Financial Statements a..
AQ
More news
News in other languages on ADAPTIMMUNE THERAPEUTICS PLC

- No features available -

More news
Analyst Recommendations on ADAPTIMMUNE THERAPEUTICS PLC
More recommendations
Chart ADAPTIMMUNE THERAPEUTICS PLC
Duration : Period :
Adaptimmune Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIMMUNE THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 9,50 $
Last Close Price 3,95 $
Spread / Highest target 330%
Spread / Average Target 141%
Spread / Lowest Target 1,27%
EPS Revisions
Managers and Directors
NameTitle
Adrian Rawcliffe Chief Executive Officer & Director
Gavin Wood Chief Financial Officer
David M. Mott Chairman
Elliot Norry Chief Medical Officer
William C. Bertrand Chief Operating Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADAPTIMMUNE THERAPEUTICS PLC-26.72%614
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628